The pharmacokinetics of antimicrobial agents administered to critically ill patients exhibit marked variability. This variability results from pathophysiological changes that occur in critically ill patients.
Introduction
Extreme pharmacokinetic (PK) variability of antimicrobial agents is encountered in critically ill patients often as a result of alterations in cardiac output, tissue perfusion, end-organ dysfunction, capillary leakage and hypoalbuminaemia (Boucher et al. 2006) . The resultant variability in drug exposure combined with the frequent presence of resistant micro-organisms may lead to suboptimal clinical outcomes. Sepsis affects one-third of patients on the intensive care unit (ICU) and is associated with a high mortality rate (Martin et al. 2003; Vincent et al. 2006) . At any given time, approximately two-thirds of patients in the ICU are receiving antimicrobial agents. Mounting evidence suggests that currently marketed antimicrobial dosing regimens may not necessarily be optimal for these patients (Kollef 1999; Roberts and Lipman 2006; Vincent et al. 2009 ). Significant changes in the clinical PK of antimicrobial agents are common in critically ill patients and dosing that does not account for these may be associated with a higher likelihood of treatment failure (Ambrose et al. 2010 ).
For antimicrobials agents, pharmacodynamics (PD) is the discipline that links drug exposure (e.g. drug concentrations) with bacterial killing or the inhibition of bacterial growth. Clinically relevant endpoints for PD studies include the antimicrobial effect, the emergence of drug resistance and antimicrobial drug toxicity. PD relationships can be established in pre-clinical and clinical contexts and both provide an insight into the magnitude of the antimicrobial drug exposure that is required for optimal effect.
The objective of this paper is to describe the antimicrobial PK variability present in critically ill patients and then to outline how PK and PD principles can be applied to deliver optimal dosing strategies.
Why is pharmacokinetics important in critically ill patients?
Pharmacokinetics describes the time-course of drug concentrations in the body. PK parameters can explain why a drug may display a different concentration-time profile in one patient A C C E P T E D M A N U S C R I P T
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4 group versus another. The apparent volume of distribution (Vd) of the drug, the clearance (Cl) and tissue distribution are all essential data for defining whether an antimicrobial dose will result in effective concentrations at the site of infection.
Volume of distribution. The Vd is a proportionality constant that relates the amount of drug in the body to the observed concentration in serum/plasma. An increase in Vd results in a reduction in peak drug concentration, an increase in trough drug concentration while the area under the concentration time curve remains unchanged. Changes in the Vd of antimicrobials in critically ill patients results from critical illness-related pathophysiology and consequent medical interventions such as fluid resuscitation. The effect on changes to Vd is predominantly restricted to hydrophilic drugs, such as β-lactams, aminoglycosides, glycopeptides, linezolid and colistin (Tang et al. 1999; Lipman et al. 2001; Boselli et al. 2005; del Mar Fernández de Gatta Garcia et al. 2007; Roberts et al. 2009a; Taccone et al. 2010; Sime et al. 2012) . These compounds typically exhibit a low Vd that often increases in critically ill patients which causes standard doses to have lower concentrations than in a non critically ill patient . Increasing extra-vascular water or severity of critical illness is associated with an increase in the Vd for hydrophilic agents such as aminoglycosides (Triginer et al. 1990; Marik 1993; Lugo and Castañeda-Hernández 1997; Balik et al. 2005) .
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5 presence of an extra-corporeal circuit (Dodge et al. 1994; Mulla et al. 2000; Mehta et al. 2007; Spriet et al. 2009 ).
Clearance. The Cl of a drug is defined as the volume of plasma completely cleared of drug per unit time. Clearance of antimicrobial agents may be due to metabolism and/or excretion. Renal excretion of antimicrobials agents is particularly affected during critical illness.
Clearance of β-lactams, fluoroquinolones, aminoglycosides, vancomycin and linezolid is altered in critically ill patients and primarily relates to changes in function of the eliminating organ (e.g. kidneys, liver, biliary tract) (Triginer et al. 1990; Tang et al. 1999; Boselli et al. 2005; del Mar Fernández de Gatta Garcia et al. 2007; Fish 2007; Roberts et al. 2009a; Taccone et al. 2010) . A reduction in glomerular filtration rate, as occurs in acute kidney injury, reduces the Cl of renally cleared antibiotics (Isla et al. 2008; Georges et al. 2009; Nicasio et al. 2009; Revilla et al. 2010; Crandon et al. 2011) . In contrast, augmented renal clearance may occur with some antimicrobials as a result of increased renal perfusion caused due to high cardiac output and low systemic vascular resistance associated with sepsis. In these cases Cl of some antimicrobials may even triple (Ambrose et al. 2010; Udy et al. 2011) . Enhanced Cl may occur with highly protein bound antimicrobial agents, such as flucloxacillin and ceftriaxone, as a result of hypoalbuminaemia (Burkhardt et al. 2007; Ulldemolins et al. 2010) . Renal replacement therapy is an effective Cl mechanism for antimicrobial agents but marked variability in performance of Cl by renal replacement therapy has been described (Tegeder et al. 1999; Krueger et al. 2003; Lipman et al. 2003; Arzuaga et al. 2005; Dagenais and Keller 2009; Bilgrami et al. 2010) . Hepatic dysfunction in critically ill patients also affects elimination of drugs, such as ciprofloxacin, moxifloxacin and ceftriaxone, which are metabolised by the liver or undergo transintestinal Cl (Heinemeyer et al. 1990; Jones et al. 1997; Stass et al. 2002) .
Target site penetration of drugs. The plasma drug concentration is the easiest and most frequently measured PK observation. For antimicrobials agents, infection mostly occurs in the
interstitial fluid (ISF) of tissues meaning that the plasma concentration is in fact a substitute for antimicrobial concentrations at the site of infection (Ryan 1993; Felton et al. 2014) . Therefore, plasma concentrations provide a reliable surrogate marker in patient groups and drugs where equivalent concentrations between plasma and tissue can be expected (Drusano 2004). However, tissue penetration studies using microdialysis catheters suggest impaired tissue penetration with some antimicrobial agents in critically ill patients (Joukhadar et al. 2001; Roberts et al. 2009a Roberts et al. , 2009b . Low ISF concentrations, as much as one-tenth the observed in plasma have been described and it has been postulated that higher than normal plasma concentrations should be targeted to drive antimicrobial drugs into tissue as a means of increasing ISF concentrations (Joukhadar et al. 2001; Roberts et al. 2009a Roberts et al. , 2009b . Other studies describing penetration of antimicrobial agents into the epithelial lining fluid (ELF) of the lung from plasma show aminoglycosides, β-lactams and glycopeptides will generate a ratio of ELF to unbound plasma free-drug concentrations of 1 than previously considered necessary, may be required for clinical cure in some critically ill patients (Tam et al. 2002) .
Why is pharmacodynamics important in critically ill patients?
PK-PD indices. Three measures of drug exposure are commonly used to link drug exposure with bacterial killing (Craig 1998; Drusano 2004; Ambrose et al. 2007 ). Firstly, the fraction of the dosing interval that the concentration of unbound (free) drug is greater than MIC (fT >MIC ); secondly, the ratio of the area under the unbound drug concentration (fAUC) time curve to the MIC (fAUC/MIC) and finally the ratio of the peak unbound drug concentration during a dosing interval to the MIC (fCmax/MIC). Table 1 describes the PK-PD indices for selected antimicrobial agents.
Toxicity. Concentration or exposure-dependent antimicrobial agent-related toxicities have been described for many antimicrobial classes. The probability of nephrotoxicty related to administration of gentamicin is related to the area-under-the-concentration time curve (Rybak et al. 1999 ). Concurrent administration of vancomycin results in a left-shift of the curve with an increased risk of nephrotoxicity related to lower gentamicin exposures. The risk of creatine phosphokinase elevation has been related to daptomycin trough concentration in patients with bacteremia or endocarditis (Bhavnani et al. 2010) . Trough voriconazole concentrations have been shown to correlate with the probability of neurotoxicity (Pascual et al. 2008 ). In the context of profound PK variability in critically ill patients, many patients may be at risk of toxicities if dose adjustment is not used when reduced antimicrobial Cl is present.
Target concentrations in critically ill patients. Potential PK-PD targets,for all classes of antimicrobial agents, which may be used for therapeutic drug monitoring in critically ill patients remain poorly defined with a wide range of potential target concentrations (Table 1 ) (Roberts et al. 2010a ).
Combining PK-PD concepts in critically ill patients.
PK variability reduces the likelihood of an acceptable proportion of patients achieving the desired PK-PD targets (Tam et al. 2003; Brink et al. 2009; Blondiaux et al. 2010; Roberts et al. 2010c; Taccone et al. 2010; Ulldemolins et al. 2011; Zelenitsky et al. 2011) . Combining knowledge of each agent's specific PK and target concentrations, in critically ill patients, allows dosing regimens be altered so effective antimicrobial agents concentrations can be delivered whilst minimising the risk of toxicity (Drusano et al. 2007; Ambrose et al. 2010) . There is only relatively limited pre-clinical in vivo data to support the use of extended infusions for administering β-lactam antibiotics. Ceftazidime delivered by infusion is superior to bolus administration especially in leukopenic rats (Roosendaal et al. 1985 (Roosendaal et al. , 1986 (Roosendaal et al. , 1989 . In vitro data also supports the use of infusions particularly against organisms with reduced susceptibility ( Relatively few studies have assessed the impact of TDM in critically ill patients (Sime et al. 2012 ). The most compelling evidence is for aminoglycosides where TDM has been shown to reduce toxicity and length of hospital stay, and mortality in patients with Gram negative infections (van
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In Bayesian dose adaptation, the dose of the drug is adjusted to optimise the individual patient's exposure. Information about the specific patient, in the form of plasma drug concentrations, and a population PK model, from a relevant population, are utilised to determine the actual PK in the subject. This data can then be used to develop more specific dosing regimens individualised to the subject's needs. As the number of blood sample measurements of a new subject increases, the estimates of the PK parameters become less informed by the population and more by the individual which increases the accuracy of subsequent predictions.
An example of Bayesian dosing in practice. A critically ill patient could be given the first dose of a chosen antimicrobial at the standard dosage. During the first dosage interval, 2-3 blood samples could then be taken, at maximally informative PK sampling times, to estimate the PK of the antimicrobial. The PK samples would then be assayed in the clinic and the drug concentrations inputted into a dose optimisation software package capable of performing MAP Bayesian estimation.
The dosage could then be adjusted to deliver the next dose with a PK exposure that is optimal for the individual patient.
There are a number of software packages which may be used for dosage adaption (Fuchs et al. 2013) . Optimised dosing using an estimation of an individual's PK to identify the optimal dosage has not been undertaken with anti-bacterial agent. Pilot studies, within other infectious diseases areas, have demonstrated with HIV drugs in paediatric patients and in the management of invasive pulmonary aspergillosis with voriconazole (Neely and Jelliffe 2010; Hope et al. 2013) . The impact of dosage adaptation on patient outcome requires further study.
Summary
Infection remains a significant problem in critically ill patients. Mortality from sepsis has not reduced in the last twenty years. The emergence of multi-drug resistant pathogens and the limited supply of new antimicrobial agents make treatment of infection in critically ill patients an even more concerning healthcare issue. The pathophysiological changes of critical illness result in marked PK variability between patients. This variability can lead to under-dosing (treatment failure) or overdosing which may be associated with drug toxicity. Limited information is available on the optimal drug concentrations and exposures required to treat infections in critically ill patients. (Felton et al. 2012 ).] Tables   Table 1. Proposed optimal PK-PD indices and associated PK-PD targets for selected 
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